|
|||
2012-01-04 10:00:00 CET 2012-01-04 10:00:40 CET REGULATED INFORMATION Biotie Therapies - Company AnnouncementChange in the number of votes relating to Biotie Therapies Corp.'s sharesBiotie Therapies Corp. Stock Exchange Release 4 January 2012 at 11.00 a.m. Change in the number of votes relating to Biotie Therapies Corp.'s shares The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"), Biotie Therapies Holding AG (previously Synosia Therapeutics Holding AG) has conveyed Biotie shares Biotie shares against consideration pursuant to the option programs as follows: December 2011 Total Options outstanding % of the total amount of shares (5-12/2011) 137,152 4,872,788 9,759,192 2.5 The conveyance of Biotie shares relates to the option plan of Synosia Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia") acquired by Biotie in February 2011. According to such Synosia share option plan, options have been granted to employees, former directors and consultants. In connection with the completion of the acquisition of Synosia, the option plan was amended so that instead of shares in Synosia an aggregate maximum of 14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued these 14,912,155 shares to its current subsidiary Synosia in connection with the acquisition to be further conveyed to the option holders when they potentially exercise their option rights in accordance with the terms and conditions of the option program. The conveyed shares previously held by the Company's subsidiary have not carried any voting rights. The parent company Biotie does not own any treasury shares. The conveyance does not affect the number of registered shares. After the conveyances the changes are as follows: The increase of A total amount of The number of the The total number of vote of the voting rights: Company´s share registered shares Company held by the Group December 2011 December 2011: 137,152 377,555,090 10,039,367 387,594,457 Turku, 4 January 2012 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900 e-mail: virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com [HUG#1575020] |
|||
|